Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Biopharma targeting efficiency and AI savings to support pipeline growth
- A UK-based biopharma company has unveiled a three-year restructuring program designed to deliver £1.9 billion ($2.5 billion) in annual cost savings by 2029 as it prepares for upcoming patent expiries and targets more than £40 billion in annual sales by 2031, as reported by Fierce Pharma.
- Approximately half of the savings will come from procurement, supply chain and process simplification, with the remainder coming from reallocating resources from mature products to specialty medicines. The business will also use AI to streamline operations and accelerate development while reinvesting most savings into its late-stage pipeline.
Prediction markets to launch on clinical trials and FDA decisions
- According to Reuters, Kalshi announced it will launch prediction markets on late-stage clinical trial results and U.S. Food and Drug Administration regulatory decisions. The contracts will allow traders to bet on the success or failure of specific drugs rather than entire pharmaceutical companies, with outcomes tied to predefined public documents such as ClinicalTrials.gov endpoints or FDA approval letters.
- Kalshi said it will require employment verification and prohibit trading by anyone possessing material nonpublic information to address insider information concerns.
FDA releases new draft guidance for GLP-1 generics
- The FDA updated its draft guidance for generic versions of GLP-1 weight loss drugs. The revisions provide additional recommendations for controlling active-ingredient-related impurities, which could help generic manufacturers prepare for eventual market entry while addressing safety concerns.
- According to Endpoints News, the guidance comes amid growing scrutiny of compounded GLP-1 products. The FDA has warned about dosing errors and other safety risks associated with compounded semaglutide and tirzepatide products, reporting over 1,500 adverse event reports tied to major GLP-1 drugs as of May 31, 2026.
Biotech companies access public markets through reverse merger deals
- Two private biotechnology companies announced this week they are accessing the public markets through reverse merger transactions with existing Nasdaq-listed companies, raising a combined $478 million in new financing to support their development.
- The deals highlight a continuing trend in biotech where venture-backed companies use reverse mergers coupled with large private financings as an alternative to traditional initial public offerings, allowing them to obtain public-market access and significant capital while avoiding some of the uncertainties of a conventional public offering, according to BioSpace.
Consumer genetic testing expansion targets early disease detection
- A laboratory services company launched a direct-to-consumer genetic test that analyzes 163 genes to assess risk for more than 100 hereditary conditions, including cancers, cardiovascular diseases and neurological disorders. The test also provides insights into medication response and certain performance-related traits.
- According to Fierce Biotech, the offering is designed to promote earlier disease detection and preventive care, combining genetic testing with access to licensed genetic counselors.
For more insights in life sciences, check out RSM’s industry outlook.
